With its core business activity focusing on the sales, marketing and distribution of biopharmaceutical products,

GENESIS Pharma has developed strategic alliances with 13 leading companies in the global biotechnology market, such as Amgen, Biogen Idec, Celgene, Cephalon, Pharmamar, Shire and Vifor.

The company has launched and marketed a unique portfolio of innovative biopharmaceutical products in Greece and Cyprus, principally within the specialty therapeutic areas of the Central Nervous System, Haematology, Nephrology and Oncology. Many of the company's products treat rare chronic or life-threatening diseases and most of them address previously unmet or underserved clinical needs.

Message from the Board of Directors

Welcome to the GENESIS Pharma website.

In 1997, based on the vision of engaging in progressive and innovative commercial activity, GENESIS Pharma took full advantage of new developments in pharmaceutical biotechnology. Today, these developments are based on research and knowledge on the human genetic code (DNA) and produce innovative medicines for the treatment of medical conditions that could not be treated in the past. The development in biotechnology was our inspiration.

Since then, GENESIS Pharma has been a partner of choice of some of the leading multinational biopharmaceutical companies, such as Amgen, Biogen Idec, Celgene, Cephalon, Pharmamar, Shire and Vifor, for the sale and marketing of biopharmaceutical products in multiple specialty therapeutic areas, mainly for the treatment of chronic, life-threatening and rare diseases. We invite you to explore our website, and hope you will find it a useful as well as a stimulating tool in order to learn more about our company, our principles and the areas of our expertise.

Sincerely,

On behalf of GENESIS Pharma's Board of Directors

Alex Jacovides             Costas Evripides
President                        C.E.O.

Vision and Mission
In 1996, when the idea of setting up a company to exploit the opportunities opening up in the pharmaceutical biotechnology sector was being conceived, the founding partners wrote down a simple statement based on the shared values of hard work, integrity, and commitment to excellence:

"To set up and manage the best Pharmaceutical Company in Greece"

GENESIS Pharma's strong performance to date is a testament to this vision. The company also has a clear and well-documented mission statement in order to achieve further expansion by establishing:

"A prominent regional presence in Southeast Europe through partnerships with key biotech companies and to ensure outstanding market performance"

GENESIS Pharma's strategic objectives include establishing new partnerships and enriching the product portfolio, achieving rapid sales growth for newly launched products as well as further developing existing products.

History

1997

GENESIS Pharma was founded as the first Greek pharmaceutical company to focus on the sales and marketing of specialized biopharmaceutical products.
Exclusive Agreement signed with Biogen for Avonex® in Greece.
Exclusive Agreement signed with Vifor for Venofer® in Greece.

1998

Distribution Agreement with Lafon (acquired by Cephalon) for Modiodal®

1999

GENESIS Pharma (Cyprus) Ltd. is established.

2000

Distribution Agreement with Amgen for Aranesp®in Greece and Cyprus.

2001

GENESIS Pharma establishes a representative office in Romania.
"Avonex Distributor of the Year" Award, by Biogen for Avonex® .
GENESIS Pharma (Cyprus) Ltd. becomes a wholly-owned subsidiary of the company.

2002

Distribution Agreements with Amgen for the distribution of Granulokine®and Neulasta®in Greece and Kineret®in Greece and Cyprus.
Distribution Agreements with Shire for Xagrid®in Greece and Cyprus.
"Avonex Distributor of the Year" Award, by Biogen for Avonex® .

2003

"Corporate Social Responsibility" Award (Annual National Advertising & PR Congress) for an awareness-raising programme for Multiple Sclerosis patients in Greece.
"Excellence and Outstanding Sales Performance" Award, by Amgen, for the sales of Amgen products in Greece and Cyprus.
Voted 8th Company in the 2003 Best Workplaces® Competition in Greece.
"Avonex Distributor of the Year" Award, by Biogen Idec for Avonex® .

2004

GENESIS Pharma establishes a representative office in Bulgaria
Awarded "Certificate of Recognition" at The Economist Corporate Social Responsibility Forum, for outstanding achievement in corporate social responsibility and sustained business performance.
Voted 7th in the 2004 Best Workplaces® Competition in Greece.
"Avonex Distributor of the Year" Award, by Biogen for Avonex®

2005

Voted 5th in the 2005 Best Workplaces® Competition in Greece
Voted among the top 100 companies to work for in the 2005 Best Workplaces® Competition in Europe.
"Avonex Distributor of the Year" Award, by Biogen for Avonex®

2006

Distribution Agreement s with Alfacell Corporation for ONCONASE®
Distribution Agreement with IDM Pharma for Mepact
Distribution Agreement with Celgene Corporation for Revlimid.
Distribution Agreements with Amgen for Mimpara and Kepivance.
Distribution Agreement with Shire for Fosrenol.
Mr C.Evripides, GENESIS Pharma CEO, was voted as the "Dynamic Entrepreneur of the Year 2006" in the international competition «Entrepreneur Of The Year".
GENESIS Pharma has been listed No. 316 among the fastest growing European companies included in the 2006 Europe's 500 Listing, the annual ranking of high growth, job-creating companies published by Europe's 500 - Entrepreneurs for Growth.
"Avonex Distributor of the Year" Award, by Biogen for Avonex®
Voted 3rd in the 2006 Best Workplaces® Competition in Greece
Voted among the top 100 companies to work for in the 2006
Best Workplaces® Competition in Europe

2007

Renewal of distribution agreement with Biogen Idec for Avonex
Distribution agreement with Biogen Idec for Tysabri.
Distribution Agreement with PharmaMar for Yondelis
Voted 4th in the 2007 Best Workplaces® Competition in Greece and awarded (special commendation) as the sole company in Greece to have been voted onto this list for six consecutive years.
Voted, for three consecutive years, among the top 100 companies to work for, in the 2007 Best Workplaces® Competition in Europe.
"Avonex Distributor of the Year" Award, by Biogen for Avonex® .
"Best Tysabri Launch Worldwide" for our launch of Tysabri in Greece, by Biogen
Distribution agreement with CellSeed Inc. for Cell-Sheet
Renewal of distribution agreements for the products (Aranesp, Neulasta,
Granulokine, Mimpara, Kineret, Kepivance) of Amgen

2008

Voted 4th in the 2008 Best Workplaces Competition in Greece
Voted, for four consecutive years, among the top 100 companies to work for, in the 2008 Best Workplaces® Competition in Europe.
"Avonex Distributor of the Year" Award, by Biogen for Avonex® .
Renewal of distribution agreement with Celgene for Revlimid
Distribution agreements with Celgene for Thalidomide, Refludan and Vidaza
Distribution agreements with Biovitrum for Kineret and Kepivance after the acquisition of Kepivance and licensing of Kineret by Biovitrum from Amgen.

2009

Voted 8th in the 2009 Best Workplaces® Competition in Greece
Distribution Agreement with Shire for Mezavant

Products

GENESIS Pharma engages in the sales and marketing of a unique portfolio of branded biopharmaceutical products principally within the specialty therapeutic areas of Oncology, Hematology, Nephrology and the Central Nervous System (CNS).

Many of these products treat rare chronic or life-threatening diseases and most of them address previously unmet or underserved clinical needs.

Products marketed and sold by GENESIS Pharma are:

ARANESP® (Darbepoetin alpha)
Amgen Europe BV

AVONEX® (Interferon Beta-1a)
Biogen Idec Ltd

FERINJECT (Intravenous Iron Carboxymaltose)
Vifor France SA

FOSRENOL® (Lanthanum carbonate)
Shire Pharmaceutical Contracts Ltd

GLIADEL® Wafer (Polifeprosan 20 with carmustine implant)
Eisai Inc

GRANULOKINE® (Filgrastim)
Amgen Europe BV

KEPIVANCE® (Palifermin)
Swedish Orphan Biovitrum AB

KINERET® (Anakinra)
Swedish Orphan Biovitrum AB

MEPACT (Mifamurtide)
Takeda Pharmaceutical Europe Ltd

MEZAVANT (Mesalazine)
Shire Pharmaceutical Contracts Ltd

MIMPARA® (Cinacalcet)
Amgen Europe BV

MODIODAL® (Modafinil)
Cephalon Europe

MYOCET (Doxorubicin HCl)
Cephalon Europe

NEULASTA® (Pegfilgrastim)
Amgen Europe BV

REFLUDAN® (Lepirudin)
Celgene Europe Ltd

REVLIMID® (Lenalidomide)
Celgene Europe Ltd

THALIDOMIDE CELGENE® (Thalidomide)
Celgene Europe Ltd

TYSABRI® (Natalizumab)
Biogen Idec Ltd- Pharma International Ltd

VENOFER® (IV Iron)
Vifor France SA

VIDAZA (Azacitidine)
Celgene Europe Ltd

XAGRID® (Anagrelide Hydrochloride)
Shire Pharmaceutical Contracts Ltd

YONDELIS® (Trabectedin)
PharmaMar SA